You are viewing an old version of this page. View the current version.

Compare with Current View Page History

« Previous Version 52 Next »

Questions:

  1. Is screening considered visit 1, or is it to include the subject into the study? SDTM team agreed to change to VISIT 1 instead of SCREENING.
  2. Are these Real World Evidence (RWE) studies only or clinical trials?  They can be both, we will concentrate on Trials and not mention RWE in this supplement.
  3. Should both endpoints be shown in one efficacy dataset or two? I will be showing 2 datasets.
  4. What is a good surface area to use for the child subject?   
  5. Should i use Male and 8 years? please advise.

This section illustrates example analysis datasets for the following endpoints:

  • Percent change in ejection fraction over time
  • Decline in ejection fraction over a time period (1 year) grouped by a decline greater than 10.0%.
  • Percent change in NTproBNP over a period of time (1 year)

Source Data

The SDTM examples used as the source data are from Section 2.1, Basic CMR Tests - Systolic Function. The CV dataset contains 16 rows, 1-8 for visit 1 and 9-16 for visit 6. Of these rows, the CVTESTCD = "LVEF_C" and CVTESTCD = "RVEF_C" representing the Ventricular Ejection Fraction, Calculated (%) for left and right were selected for the analysis. The LB dataset test where LBTESTCD = "BNPPRONT" was used to add the value of BNPPRONT to compute the percent change over time, and then it was added as a potential covariate in each row for the last analysis.  As in all ADaM datasets, the Subject Level Analysis Dataset (ADSL) was merged in to the SDTM datasets to capture all the necessary demographics, treatments and other required variables for analysis of the data.

For the ADSL here is an additional SDTM dataset showing variables needed for ADSL.

Analysis Datasets

The example analysis dataset includes treatment and demographic information drawn from the ADSL, defined in the Metadata Table below. In this example, only some of the required variables, plus important stratification variables from ADSL, are shown for illustrative purposes. For example, one variable added; body surface area at baseline (BSABL)  was computed for baseline records in ADSL. However, since the subjects are children, the body surface area changes over time. Therefore, it would probably be necessary to have a separate dataset to represent this over time.

The table below shows the example analysis datasets and unique parameters for this example. The Subject Level Analysis Dataset (ADSL)  is a necessary component in the creation process of subsequent analysis datasets for human trials. The ADSL incorporates demographics, treatment groups, study dates, and stratification variables. In this example, the ADSL is not illustrated, but serves as a source for standard ADaM variables. Additional information can be found in Section 2.3.1 of the ADaM Implementation Guide (ADaMIG) v1.3.

The ADCVEF dataset includes tests pertinent to this analysis, those for which CVTESTCD is equal to "LVEF_C" or "RVEF_C". The relationship dataset RELREC illustrates the relationship between datasets. 

The ADCVNTRP dataset is a subset of the Laboratory Results (LB) SDTM dataset, for which LBTESTCD is equal to "BNPPRONT". In this case, many lab draws may occur throughout the year, but only those linked to a specific visit are included. By subsetting the LB dataset with LBLNKID not missing, laboratory data that aligns with CV data can be filtered out and sorted using USUBJID and VISIT. If LBLNKID is not available, a windowing strategy could be used to select the laboratory draw closest to that visit for merging with CV, computed in AVISIT.

ADCMRI is an efficacy analysis dataset with only a few records for more complex modeling of changes in ejection fraction, plus the ProB-type test results. It is an ADaM Basic Data Structure (BDS) dataset, with additional variables added from ADCVEF.

Analysis Datasets

Parameter Value List - ADCVNTP [ADCVNTP]

Analysis Datasets

The subsequent section provides the data structures for the example ADaM datasets. In this example, columns for derived variables BASE, CHG, PCHG and CHGCAT1 have been added to facilitate analyses of the efficacy endpoints. Specifically, example demographic data for ADSL were created for an 8 year old male. Also, a custom variable for BSA at baseline (BSABASE), was added from ADSL.

ADCVNTP Variable Metadata

Example 1 

This example dataset shows the findings and additional analysis variables associated with:

  • Left Ventricular Ejection Fraction, Calculated (%)
  • Right Ventricular Ejection Fraction, Calculated (%)
  • N-Terminal ProB-type Natriuretic Peptide (pg/mL)

Rows 1-2:Show the baseline CMR ejection fraction measurements for participant 101 at VISIT 1.
Row 3:Shows the baseline NTProbTest for participant 101 at VISIT 1.
Rows 4-5:Show the CMR ejection fraction measurements for participant 101 at VISIT 6.
Row 6:Shows the NTProbTest for participant 101 at VISIT 6.
$titleHtml

adcvntpr.xpt

RowSTUDYIDUSUBJIDASEQBSABASEPARAMPARAMCDPARAMNAVALAVISITAVISITNVISITADTABLFLBASECHGPCHGCHGCAT1TRT01PITTFLAAGEAGEAGEUSEXSRCDOMSRCSEQ
1DMD-EFLGEDMD-EFLGE-10110.65Left Ventricular Ejection Fraction, Calculated (%)LVEFC167Visit 1 (Baseline)1VISIT 116MAY2022Y67


Treatment AY8.258YEARSMCV3
2DMD-EFLGEDMD-EFLGE-10120.65Right Ventricular Ejection Fraction, Calculated (%)RVEFC274Visit 1 (Baseline))1VISIT 116MAY2022Y74


Treatment AY8.258YEARSMCV7
3DMD-EFLGEDMD-EFLGE-10130.65N-Terminal ProB-type Natriuretic Peptide (IU/L)BNPPRONT340Visit 1 (Baseline)1VISIT 116MAY2022Y40


Treatment AY8.258YEARSMLB1
4DMD-EFLGEDMD-EFLGE-10140.65Left Ventricular Ejection Fraction, Calculated (%)LVEFC160Visit 6 (1 Year)6VISIT 601JUN2023
67-7-10.447761Decline >=10.0Treatment AY8.258YEARSMCV11
5DMD-EFLGEDMD-EFLGE-10150.65Right Ventricular Ejection Fraction, Calculated (%)RVEFC261Visit 6 (1 Year)6VISIT 601JUN2023
74-13-17.567568Decline >=10.0Treatment AY8.258YEARSMCV15
6DMD-EFLGEDMD-EFLGE-10160.65N-Terminal ProB-type Natriuretic Peptide (IU/L)BNPPRONT3900Visit 6 (1 Year)6VISIT 101JUN2023
408602,150
Treatment AY8.258YEARSMLB2
$warningHtml

Dataset Wrapper Debug Message

Please add a row column to your dataset.

Example 2 

The dataset above can also be set up to provide multivariate analyses by taking the lab tests of interest, transposing and merging with the ADCVNTPP dataset. In that case, the records from LB are not needed as a row.

The variables transposed and merged to the rows created from CV are:

DatasetValueWhere Variable Variable Label
ADCVNTPAVALPARAMCD = "BNPPRONT"BNPPRONTN-Terminal ProB-type Natriuretic Peptide (IU/L)
ADCVNTPCHGPARAMCD = "BNPPRONT"BNPCHGN-Term ProB-type N Pep Change Category

$titleHtml

adcvntp.xpt

RowSTUDYIDUSUBJIDASEQBSABASEBNPPRONTBNPCHGPARAMPARAMCDPARAMNAVALAVISITAVISITNVISITADTABLFLBASECHGPCHGTRT01PITTFLAGEAGEUSEXSRCDOMSRCSEQ
1DMD-EFLGEDMD-EFLGE-10110.6540
Left Ventricular Ejection Fraction, Calculated (%)LVEFC167Visit 1 (Baseline)1VISIT 116MAY2022Y67

Treatment AY8YEARSMCV3
2DMD-EFLGEDMD-EFLGE-10120.6540
Right Ventricular Ejection Fraction, Calculated (%)RVEFC274Visit 1 (Baseline)1VISIT 116MAY2022Y74

Treatment AY8YEARSMCV7
3DMD-EFLGEDMD-EFLGE-10130.659002150Left Ventricular Ejection Fraction, Calculated (%)LVEFC160Visit 6 (1 Year)6VISIT 601JUN2023
67-7-10.447761Treatment AY8YEARSMCV11
4DMD-EFLGEDMD-EFLGE-10140.659002150Right Ventricular Ejection Fraction, Calculated (%)RVEFC261Visit 6 (1 Year)6VISIT 601JUN2023
74-13-17.567568Treatment AY8YEARSMCV15
$warningHtml

Example Analysis Results Metadata (ARM) Tables

This table may be included in the submission package for regulatory agencies. It describes the analyses conducted for the study (usually limited to primary and secondary  endpoints) with details on data and analysis procedures used. The first example uses the dataset ADCVNTPR, selecting for the parameter "N-Terminal ProB-type Natriuretic Peptide (IU/L)".

Display

Table 14.xx.xx Percent change in NTproBNP over a period of time (yearly)

Analysis ResultComparison of Percent Change of NTproBNP for the Treatment Groups Over Time (quarterly or yearly)
Analysis Variables(s)PCHG
Analysis ReasonPrimary efficacy endpoint as prespecified in the SAP
Analysis PurposePrimary outcome measure

Data References

(incl. selection criteria)

PARAMCD = "BNPPRONT"

Where ITTFL = "Y"

Documentation

 The mixed model using lsmeans to compare treatment groups

Programming Statements 

(Add programming language statements here: SAS, R, etc.)

PROC MIXED DATA=ADCVNTPR;

WHERE PARAMCD = "BNPPRONT";

CLASS STUYDID TRT01P AVISITN;

MODEL PCHG=AVISITN*TRT01P/Solution;

RANDOM INTERCEPT / SUBJECT=STUYDID TYPE=UN;

LSMEANS TRT01P*AVISITN/ CL PDIFF;

RUN;

Display

Table 14.xx.xx Percent Change in Left Ventricular Ejection Fraction Over Time

Analysis ResultComparison of Percent Change of Ejection Fraction for the Treatment Groups Over Time (quarterly or yearly)
Analysis Variables(s)PCHG
Analysis ReasonPrimary efficacy endpoint as prespecified in the SAP
Analysis PurposePrimary outcome measure

Data References

(incl. selection criteria)

PARAMCD = "LVEFC"

Where ITTFL = "Y"

Documentation

 The mixed model using lsmeans to compare treatment groups

Programming Statements 

(Add programming language statements here: SAS, R, etc.)

PROC MIXED DATA=ADCVNTP;

CLASS STUYDID TRT01P AVISITN;

MODEL PCHG=AVISITN*TRT01P/Solution;

RANDOM INTERCEPT / SUBJECT=STUYDID TYPE=UN;

LSMEANS TRT01P*AVISITN/ CL PDIFF;

RUN;

Ejection Fraction

  • change in ejection fraction, would expect a decline in EF 2-3% per year, would prefer an improvement or no change. Concerning if rapid progression, 10% decline or more, for example.

NTproBNP

  • % change over a period of time – a decrease would mean improvement, annually is appropriate

SDTM Examples: Basic CMR Tests - Systolic Function

  • No labels